# LIDOPRO- capsaicin, lidocaine, menthol, and methyl salicylate ointment Asclemed USA, Inc.

-----

#### LidoPro 4%

#### <u>Methemoglobinemia</u>

Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine-containing products and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.

#### **Active Ingredient**

Capsaicin 0.0325%

#### Purpose

**Topical Analgesic** 

#### **Active Ingredient**

Lidocaine HCL 4%

#### Purpose

**Topical Analgesic** 

#### Active Ingredient

Menthol 10%

#### Purpose

**Topical Analgesic** 

## **Active Ingredient**

Methyl Salicylate 27.5%

## Purpose

**Topical Analgesic** 

## Uses:

Temporarily relieves minor aches and muscles pains associated with:

- arthritis
- simple back pain
- strains
- muscle soreness

## Warnings

## For external use only

## Do not use

- on open wounds, cuts, damaged or infected skin
- with bandage or a heating pad
- if condition worsens or symptoms persists for more than 7 days
- excessive skin irritation occurs

## Ask a doctor before use if

• you are allergic to any ingredients, PABA, aspirin products or sulfa

## When using this product

• avoid contact with eyes, genitals, and other mucus membranes. If eye contact occurs, rinse thoroughly with water.

## If pregnant or breast feeding,

ask a health professional before use.

## Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away. Package not child resistant.

## Store

at 20<sup>°</sup>C - 25<sup>°</sup>C (68<sup>°</sup>F - 77<sup>°</sup>F)

#### Directions

### Adults 18 years and children 12 years and older:

- apply product directly to affected area
- product may be used as necessary, but should not be used more than four times per day.
- wash hands immediately afterwards

### Children 12 years or younger: ask a doctor

#### **Inactive Ingredients**

Allantoin, Aloe Barbadensis Leaf Juice, Ammonium Acryloyldimethyltaurate/VP Copolymer, Cetyl Alcohol, Chamomilla Recutita Matricaria Flower Extract, Dimethicone, Disodium EDTA, Ethylhexylglycerin, Glycerin, Glyceryl Stearate, Inulin Lauryl Carbamate, PEG-100 Stearate, Phenoxyethanol, Stearic Acid, Triethanolamine, Water.

(01) 0 0376420 03812 2

(17) 200205 (10) XXXXXXXX

(21) 125133

#### For Questions or Comments

Please Email info@TerrainRX.com

#### **Relabeled by:**

Enovachem PHARMACEUTICALS

Torrance, CA 90501

Made in the U.S.A. Patent Pending

## **Principal Display Panel**





LidoPro Topical Pain Relief Ointment NDC: 76420-038-12 S/N:125133 Qty: 121

LidoPro Topical Pain Relief Ointment NDC: 76420-038-12 S/N:125133 Qty: 121

LidoPro Topical Pain Relief Ointment NDC: 76420-038-12 S/N:125133 Qty: 121

## LIDOPRO

capsaicin, lidocaine, menthol, and methyl salicylate ointment

#### **Product Information**

| Product | Туре |
|---------|------|
|---------|------|

Route of Administration

TOPICAL

| Active Ingredient/Active Moiety  |                                      |                      |  |  |  |
|--|--------------------------------------|----------------------|--|--|--|
| Ingredient Name  | <b>Basis of Strength</b>             | Strength             |  |  |  |
| CAPSAICIN (UNII: S07044R1ZM) (CAPSAICIN - UNII:S07044R1ZM)                     | CAPSAICIN                            | 0.000325 g<br>in 1 g |  |  |  |
| LIDOCAINE HYDROCHLORIDE (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987)       | LIDOCAINE HYDROCHLORIDE<br>ANHYDROUS | 0.04 g in 1 g        |  |  |  |
| MENTHOL (UNII: L7T10EIP3A) (MENTHOL - UNII:L7T10EIP3A)                         | MENTHOL                              | 0.1 g in 1 g         |  |  |  |
| <b>METHYL SALICYLATE</b> (UNII: LAV5U5022Y) (SALICYLIC ACID - UNII:0414PZ4LPZ) | METHYL SALICYLATE                    | 0.275 g in 1 g       |  |  |  |

| Ingredient Name  | Strength |
|--|----------|
| ALLANTOIN (UNII: 344S277G0Z)                                     |          |
| ALOE VERA LEAF (UNII: ZY81Z83H0X)                                |          |
| AMMONIUM ACRYLOYLDIMETHYLTAURATE/VP COPOLYMER (UNII: W59H9296ZG) |          |
| CETYL ALCOHOL (UNII: 936JST6JCN)                                 |          |
| CHAMOMILE (UNII: FGL3685T2X)                                     |          |
| DIMETHICONE (UNII: 92RU3N3Y1O)                                   |          |
| EDETATE DISODIUM (UNII: 7FLD91C86K)                              |          |
| ETHYLHEXYLGLYCERIN (UNII: 147D247K3P)                            |          |
| GLYCERIN (UNII: PDC6A3C0OX)                                      |          |
| GLYCERYL MONOSTEARATE (UNII: 2300U9XXE4)                         |          |
| PEG-100 STEARATE (UNII: YD01N1999R)                              |          |
| TROLAMINE (UNII: 903K93S3TK)                                     |          |
| WATER (UNII: 059QF0KO0R)   |          |
|  |          |
|  |          |
| Packaging  |          |
| гаскаушу   |          |

| #                     | ltem Code             | Package Description                                     | Marketing Start<br>Date | Marketing End<br>Date |  |  |
|-----------------------|-----------------------|---|-------------------------|-----------------------|--|--|
| 1                     |                       | 121 g in 1 BOTTLE; Type 0: Not a Combination<br>Product | 02/05/2020              |                       |  |  |
|                       |                       |   |                         |                       |  |  |
| Marketing Information |                       |   |                         |                       |  |  |
|                       | Marketing<br>Category | Application Number or Monograph<br>Citation             | Marketing Start<br>Date | Marketing End<br>Date |  |  |
| 01                    | FC Monograph Drug     | M017  | 01/01/2014              |                       |  |  |

Labeler - Asclemed USA, Inc. (059888437)

# Establishment

| Name                            | Address | ID/FEI    | <b>Business Operations</b> |
|---------------------------------|---------|-----------|----------------------------|
| ASCLEMED USA INC. DBA ENOVACHEM |         | 059888437 | relabel(76420-038)         |

Revised: 10/2023

Asclemed USA, Inc.